Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Abroad (travel likely)RecruitingPHASE2

Conditions

Epilepsy · Seizures, Epileptic

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Green Leaf Clinical Trials, LLC, Jacksonville, Florida, United States

  • Visionary Investigators Network, Miami, Florida, United States

  • Prince of Wales Hospital, Randwick, New South Wales, Australia

  • Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

  • Westmead Hospital, Sydney, New South Wales, Australia

  • Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia

  • Box Hill Hospital, Box Hill, Victoria, Australia

  • The Austin Hospital, Heidelberg, Victoria, Australia

  • The Alfred Hospital, Melbourne, Victoria, Australia

    Contact: Study coordinator (Jack Germaine) · J.Germaine@alfred.org.au · +61 3 9076 2029
    Contact: Principal Investigator (Terence O'Brien, MD)
  • The Royal Melbourne Hospital, Parkville, Victoria, Australia

Study leads
  • Maciej Gasior, MD, PhD

    Study Director

    Supernus Pharmaceuticals